Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Careggi Hospital
This study is mainly based on a registry of 2000 consecutive patients with acute coronary syndrome who received invasive treatment and for whom platelet reactivity after clopidogrel treatment will be prospectively assessed.
In the acute phase, blood samples for platelet reactivity assessment will be obtained 12 to 18 hours from 600 mg clopidogrel loading. Platelet-rich plasma, obtained by centrifuging whole blood for 10 min at 200 g, was stimulated with 10 M adenosine 5'-diphosphate (ADP) and residual aggregation will be assessed using a APACT 4 light transmittance aggregometer. Platelet aggregation (according to the Born's method) will be evaluated considering the maximal percentage of platelet aggregation in response to stimulus. Patients with platelet aggregation by 10 µmol ADP ≥ 90th percentile of controls (70%) will be defined as non-responders. The assessment of platelet reactivity will be repeated at 6 months. The importance of concomitant aspirin resistance will be also evaluated in such of patients.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
acute coronary syndrome
invasive treatment
You may not be if
in-hospital death that was not due to stent thrombosis,
anticipated poor compliance to dual antipletelet treatment for at least 6 months,